Novartis

After Novartis Pact, Macrocycle Shop Unnatural Products Gets $45M Series B

Novartis, SciNeuro to Work Together on Preclinical Amyloid-Targeting Drug for Alzheimer’s

Keep an Eye on These 15 Biotech Companies in 2026 

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall

After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar

Novartis Breaks Ground on San Diego Biomedical R&D Site

Biotech in 2025: A Retrospective 

Burnout Common but Regrets Are Not in Allergy, Immunology

TerraPower Commits $450M to Build Radioisotope Production Plant

Novartis Licenses Radiopharma Asset From Chinese Biotech for $50M Upfront

FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna)

AstraZeneca Leads Big Pharma’s AI Clinical Trials Revolution with Real-World Patient Impact

Fragment Merging – and Flipping – on the Leucine Zipper of MITF

Novartis to Buy US-Based Biotech Firm Excellergy for up to US$2 Billion

Insufficient Source Data to Report on Novartis‑Excellergy Deal

JPM26: Filling C-Suites, Union Square—And Elevators—With Pink

Health Equity & Access Weekly Roundup: February 20, 2026

Calcium Score Predictive of ASCVD Risk From Elevated Lp(a)

Proteasomes: A Novel Approach to Target the Immune System

A Protein Found in the GI Tract Can Neutralize Many Bacteria

CMS's Medicare Price Negotiations Start Round Three

Enliven’s Phase 1 Leukemia Pill Data Look Competitive with Novartis and Terns

Novartis Says Generics to Erode $4B From 2026 Sales

With De-Risking the Mantra, Novartis Expands Presence in RNAi: Narasimhan in Conversation

Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors

Novartis to Divest India Unit to Private Equity-Led Consortium for $159M

Novartis Acquisition Spin-Off Pioneers RNA Therapeutics for the Heart

Facing Talent Crunch, Radiopharma Field Casts a Wide Net

Viatris Settles Lawsuit Over Use of Woman’s ‘Immortal’ Cells to Power Drug Research

Industry Outlook 2026: The Impact of Novel Therapies

Chinese-Owned Syngenta to Build New £100m Bioscience Hub in UK

J&J Bets on Isomorphic for AI-Powered Drug Hunt

Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos

Six Biotech Companies in Berlin to Watch in 2026

Hiring Outlook: February Brings First YOY Job Increase Since 2022

Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations

Ex-Novartis CMO John Tsai Joins Daiichi Sankyo

2026 Cardiovascular Catalysts: Lp(a) on the Horizon

Vyriad Raises Final $25M Series B Tranche

Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility

RBC Capital Lowers Its Price Target on Bicycle Therapeutics Plc (BCYC) to $7 From $11

Bayer and Cradle Enter Collaboration to Enhance AI-Enabled Antibody Discovery and Optimization

Novartis to Build Fourth US Radiotherapy Factory in Florida 

BioAge Labs Provides Business Updates

An Opinionated Take on NEJM Highlights for Q1 of 2026

Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy

Health Care Roundup: Market Talk

JCE: Large-Cap Equity Fund With Call Options, 8.15% Yield, And 5.7% Discount

Exclusive: Oro Labs, Which Uses AI to Streamline Corporate Procurement, Raises $100 Million

Novartis to Acquire Experimental Breast Cancer Drug From Synnovation Therapeutics for $2B

Novartis to Acquire Avidity Biosciences in $12B Takeover

Novartis to Sell 70.68% Stake in Novartis India to Consortium for ₹1,446 Crore

Unnatural Products Secures $1.8B Cardio Pact with Novartis